Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer Clinical Trial

Official title:

A Phase II Randomised Controlled Trial to Determine the Efficacy of Combining the HDAC Inhibitor Sodium Valproate With EGFR Monoclonal Antibody (Panitumumab or Cetuximab) Maintenance in the First-line Treatment of Patients With RAS Wild Type Metastatic Colorectal Cancer (CRC)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05694936
• Other study ID #: VADER
• Status: Recruiting
• Phase: Phase 2
• Start date: January 23, 2023
• Est. completion date: September 2024

Study information

• Verified date: January 2023
• Source: Australasian Gastro-Intestinal Trials Group
• Contact: Sukanya Sathyamurthie
• Phone: +61 2 7208 2719
• Email: sukanya[@]gicancer.org.au
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to determine the efficacy of combining the histone deacetylase (HDAC) inhibitor sodium valproate (VPA) with anti-EGFR monoclonal antibody (panitumumab or cetuximab) maintenance in the first-line treatment of patients with RAS wild type metastatic CRC.

Description:

The primary objective is to evaluate progression free survival (PFS) in patients with RAS wild type metastatic CRC treated in the first-line with VPA plus panitumumab or cetuximab maintenance, or panitumumab or cetuximab maintenance alone. The secondary objectives are (i) to evaluate overall survival (OS) and objective response rates (ORRs; RECIST v 1.1) in patients with RAS wild type metastatic CRC treated in the first-line with VPA plus panitumumab or cetuximab maintenance, and panitumumab or cetuximab maintenance alone; and (ii) to evaluate the safety (NCI CTCAE v5.0) of first-line maintenance treatment with VPA plus panitumumab or cetuximab, and panitumumab or cetuximab maintenance alone in patients with RAS wild type metastatic CRC. The tertiary and exploratory objectives are: - To evaluate Health-Related Quality of Life (EORTC QLQ-C30 and EQ-5D-5L) in patients with RAS wild type metastatic CRC treated in the first-line with VPA plus panitumumab or cetuximab maintenance, and panitumumab or cetuximab maintenance alone. - Exploratory analyses including, but not limited to: (i) Determining whether changes in levels of histone acetylation in peripheral blood mononuclear cells (PBMCs) are associated with improved efficacy with VPA plus anti-EGFR monoclonal antibody maintenance treatment; and (ii) determining whether potential resistance-conferring mutations in circulating tumour DNA (ctDNA) are associated with efficacy outcomes in patients treated with anti-EGFR monoclonal antibody maintenance.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: September 2024
• Est. primary completion date: September 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age = 18 years.

2. Histological diagnosis of colorectal cancer.

3. Metastatic colorectal cancer that is being treated with non-curative intent. This may be because the disease is anatomically not resectable, resection is contra-indicated for any reason, or the patient refuses resection.

4. Measurable disease as assessed by CT scan (by RECIST 1.1).

5. Evidence of RAS wild type status (KRAS exons 2, 3 and 4 and NRAS exons 2, 3, and 4) as assessed by the investigators' choice of testing laboratory.

6. ECOG performance status 0, 1.

7. Suitable, as deemed by the investigator, for maintenance treatment with panitumumab or cetuximab alone or in combination with oral sodium valproate.

8. Completed four months of first-line induction treatment with fluoropyrimidine-based chemotherapy (which may be intravenous or oral, in which case 15 weeks of treatment is required; and either alone or in combination with oxaliplatin or irinotecan) and anti-EGFR monoclonal antibody (panitumumab or cetuximab) without progressive disease.

9. Prior palliative radiotherapy is allowed, provided that (i) no concurrent chemotherapy was administered, (ii) at least 2 weeks after completion of therapy has elapsed before enrolment, and (iii) any toxicities have resolved or are Grade 1. Prior fluoropyrimidine chemotherapy given concurrent with radiation as neoadjuvant treatment for rectal cancer is allowed.

10. Adequate hepatic function with serum total bilirubin < x1.5 upper limit of normal range and ALT or AST < x3 upper limit of normal range.

11. Adequate bone marrow function with platelets = 80 X 109/L; neutrophils = 1.5 X 109/L; haemoglobin = 8g/dL.

12. Adequate renal function, with calculated creatinine clearance = 50 mL/min.

13. Any abnormalities in magnesium are not > Grade 2. Any abnormalities in total calcium are not > Grade 1. Total calcium should be corrected for albumin level as per the institution's usual calculation method. Serum potassium levels should be above 4.0 mmol/L.

14. Archival formalin-fixed paraffin embedded (FFPE) tumour tissue is available for storage and use by the central laboratory.

15. Life expectancy of at least 12 weeks.

16. Women and partners of women of childbearing potential must agree to use adequate contraception uninterrupted for the duration of receiving VPA, cetuximab and panitumumab, and for an additional 2 months after the last dose of cetuximab and 6 months after the last dose of panitumumab. Adequate contraceptive measures are barrier methods (condoms, diaphragm); oral, injectable, or implant birth control; or abstinence.

17. Willing and able to comply with all study requirements, including treatment, timing and/or nature of required assessments.

18. Written informed consent including consent for donation of tumour tissue for biomarker studies and collection of peripheral blood for research.

Exclusion Criteria:

1. BRAFV600E mutant CRC.

2. CRC with HER2 IHC score of 3+. Note that IHC evaluation for HER2 amplification is required for determining eligibility. HER2 testing using ISH is not required.

3. Prior chemotherapy before first-line induction chemotherapy. Exceptions are adjuvant chemotherapy which was given in association with (i) complete resection of primary colon or rectal cancer provided there is no clinical, radiological or biochemical evidence of relapse for at least 6 months after completion of adjuvant treatment, and/or (ii) complete resection of limited colorectal metastases to liver and/or lung provided there is no clinical, radiological or biochemical evidence of relapse for at least 6 months after completion of adjuvant treatment.

4. History of life-threatening hypersensitivity reactions to panitumumab or cetuximab, or any product excipients of panitumumab or cetuximab.

5. Known hypersensitivity to sodium valproate.

6. Any other contraindication/s to sodium valproate including mitochondrial disorders and urea cycle disorders.

7. Pre-existing acute or chronic hepatic dysfunction or family history of severe hepatitis

8. Patients with systemic lupus erythematosus are eligible, however the investigator should discuss the potential risk of immune disorders with the participant, which have been noted only exceptionally during the use of VPA.

9. Patients with long QT syndrome, or QTc interval duration > 480 msec, or use of concomitant medications that significantly prolong the QTc interval.

10. Prior or current treatment with HDAC inhibitor or compounds with HDAC inhibitor-like activity, including hydroxamic acid (e.g vorinostat/zolinza, panobinostat/farydak. Belinostat/beleodaq), benzamide (tucidinostat/epidaza/chidamide), cyclic tetrapeptide (Romidepsin/Istodax) or carboxylic acid (e.g sodium valproate, phenylbutyrate) based HDAC inhibitors.

11. Active treatment with sodium valproate for non-oncological conditions.

12. Active epilepsy or convulsive conditions that require continuous use of anticonvulsants.

13. History of interstitial lung disease or pulmonary fibrosis.

14. Leptomeningeal disease as the only manifestation of malignancy.

15. Untreated/active CNS metastases (i.e., progressing, requiring ongoing corticosteroids or anticonvulsants for symptom control). Patients with CNS metastases are eligible if they have previously been successfully treated with surgery and/or radiotherapy at least 8 weeks prior to cycle 1 day 1, have ceased taking all corticosteroids and/or anticonvulsants for at least 4 weeks and if imaging within 4 weeks of cycle 1 day 1 excludes any progression.

16. Invasive malignant disease, other than CRC, diagnosed within 2 years of randomisation. Patients with non-melanotic skin cancer, carcinoma in situ of the uterine cervix, or any other cancer which was treated with curative intent > 2 years prior to randomisation and without evidence of relapse, are eligible.

17. Active infection requiring systemic therapy and/or other concurrent uncontrolled medical conditions.

18. Positive pregnancy test prior to the initiation of the study medications.

19. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate.

20. Medical, psychiatric conditions or any other reason that, as assessed by the investigator, may compromise the patient's ability to give informed consent or to comply with the protocol-specified treatments and assessments.

Related Conditions & MeSH terms

• Colorectal Neoplasms
• Metastatic Colorectal Cancer

Intervention

Drug:
• Sodium Valproate
Sodium valproate oral continuously in a twice daily dose (Initial dose of 600mg/d up-titrated to target daily dose of 20 mg/kg/d at Cycle 1 Day 13, then dose adjusted to maintain serum VPA levels within the target range of 50-100 µg/mL); Refer to arm description.
• Panitumumab
Panitumumab 6 mg/kg IV every 2 weeks or cetuximab 500 mg/m2 IV every 2 weeks; Refer to arm description.
• Cetuximab
Panitumumab 6 mg/kg IV every 2 weeks or cetuximab 500 mg/m2 IV every 2 weeks; Refer to arm description.

Locations

Country	Name	City	State
Australia	Queen Elizabeth Hospital	Adelaide	South Australia
Australia	Eben-Marie Garzina	Ballarat Central	Victoria
Australia	Southern Adelaide Local Health Network Incorporated	Bedford Park	South Australia
Australia	Eastern Health	Box Hill	Victoria
Australia	Peninsula Health	Frankston	Victoria
Australia	Austin Health	Melbourne	Victoria
Australia	Peter MacCallum Cancer Institute	Melbourne	Victoria
Australia	Royal North Shore Hospital	Saint Leonards	New South Wales
Australia	South West Healthcare	Warrnambool	Victoria

Sponsors (2)

Lead Sponsor	Collaborator
Australasian Gastro-Intestinal Trials Group	Olivia Newton-John Cancer Research Institute

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Health-related quality of life (EORTC QLQ-C30)	Health-Related Quality of Life (HRQoL) will be determined by the global and subscale scores outlined in the EORTC user manual and scoring guidelines. Scores are from 0-100, with higher scores indicating better quality of life.	12 Months from randomisation
Other	Health-related quality of life (EQ-5D-5L)	The EQ-5D-5L will be used to derive utility scores suitable for quality adjusted survival analyses. The scale has five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), each of which are scored at one of five levels ranging from no problems to extreme problems.	12 Months from radomisation
Other	Quantification of histone acetylation levels in peripheral blood mononuclear cells (PBMCs)	Exploratory analysis detecting changes in levels of histone acetylation in PBMCs during treatment	12 Months from radomisation
Other	Quantification of total circulating tumour DNA (ctDNA)	Exploratory analysis detecting the levels of ctDNA during treatment	12 Months from radomisation
Primary	Progression free survival	Progression free survival (PFS) will be defined as the interval from date of registration or randomisation to the date of first evidence of disease progression (measured by RECIST v1.1 criteria) or death whichever occurs first, in each treatment arm.	12 Months from randomisation
Secondary	Overall Survival	Overall survival (OS) will be defined as the interval from date of registration or randomisation to date of death from any cause.	12 Months from randomisation
Secondary	Objective response rates (ORRs)	ORRs will be calculated as the proportion of participants in each arm who are assessed as having a complete or partial response measured by RECIST v1.1.	12 Months from randomisation
Secondary	Quantification of the incidence of treatment-emergent adverse events according to CTCAE V5.0	Safety of each treatment arm will be assessed by evaluating the number and severity (grade) of adverse events reported according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0).	12 Months from randomisation